PACB PACIFIC BIOSCIENCES OF CALIFORNIA, INC.

CIK 0001299130 31 ready 8-Ks latest June 4, 2026, 5:19 PM ET RSS · JSON

Activity: NORMAL 2 filings / 30d vs 1 baseline

Ready 8-Ks 31

Latest filing June 4, 2026, 5:19 PM ET

Top materiality 0.85

Event mix earnings ×12 · leadership ×8 · other_material ×6

Sentiment 6 pos · 9 neg · 16 neu

Latest earnings reported 2026-Q1

Executive change recent →

Recent 8-K filings for PACB

Highest-materiality recent filing

PacBio reports preliminary Q1 rev $38.8M (flat YoY), slashes FY2024 guidance to $170-200M, cuts costs $50-75M

April 16, 2024, 7:59 PM ET earnings materiality 0.85 negative item 2.02 item 2.05 item 8.01 item 9.01 ◈ Earnings Releases ×2

Preliminary Q1 2024 revenue $38.8M, roughly flat vs $38.9M in prior-year period.
Revio shipments 28 systems in Q1; installed base reached 201 as of March 31, 2024.

Read filing →

June 4, 2026, 5:19 PM ET other material materiality 0.50 neutral item 5.02 item 5.07 item 9.01 ◈ Shareholder Votes ×4

Shareholders approve 16M share increase in equity plan at Pacific Biosciences annual meeting

Stockholders approved amendment to 2020 Equity Incentive Plan, adding 16,000,000 shares for future grants.
May 7, 2026, 7:59 PM ET earnings materiality 0.65 neutral item 2.02 item 9.01 ◈ Earnings Releases

PacBio Q1 rev flat at $37.2M; consumable record but instrument miss; FY26 guidance $165-175M

Q1 revenue $37.2M flat YoY; consumable record $21.8M (+8% YoY), instrument revenue $9.7M (-12% YoY) below expectations.
March 6, 2026, 6:59 PM ET litigation materiality 0.60 neutral item 5.02 item 7.01

PACB settles patent lawsuit with PGI, will pay $23M to $25M; CAO resigns

Michele Farmer resigns as CAO effective March 21, 2026; no severance or disagreement.
March 5, 2026, 6:59 PM ET leadership materiality 0.40 positive item 5.02 item 7.01 item 9.01

PacBio appoints Chris Gibson (Recursion co-founder) to board; effective March 3, 2026

Board expanded to 10; Gibson appointed Class I director with term expiring at 2026 annual meeting.
February 12, 2026, 6:59 PM ET earnings materiality 0.80 neutral item 2.02 item 9.01

PacBio Q4 revenue $44.6M, consumable record; GAAP net loss $40.4M, non-GAAP loss narrows

Q4 revenue $44.6M (+14% YoY); consumable revenue record $21.6M (+15% YoY).
February 3, 2026, 6:59 PM ET leadership materiality 0.30 neutral item 5.02

Pacific Biosciences CEO and COO swap interim responsibilities effective Jan 28, 2026

CEO Christian Henry assumes interim oversight of operations and R&D from COO Mark Van Oene.
February 2, 2026, 6:59 PM ET M&A materiality 0.75 positive item 1.01 item 2.01 item 7.01 item 9.01 ◈ M&A Transactions

PacBio completes sale of short-read sequencing assets to Illumina for $48.1M net cash

Sold certain short-read DNA sequencing IP and related technologies to Illumina for $50M gross; net cash proceeds $48.1M.
January 12, 2026, 6:59 PM ET earnings materiality 0.75 positive item 2.02 item 8.01 item 9.01

PacBio Q4 revenue $44.6M (+14% YoY); full year $160M (+4%); record consumables

Q4 2025 revenue ~$44.6M vs $39.2M YoY; full year ~$160M vs $154M.
November 5, 2025, 6:59 PM ET earnings materiality 0.75 neutral item 2.02 item 9.01

PacBio Q3 revenue $38.4M, net loss narrows to $38M; consumables hit record $21.3M

GAAP net loss $38.0M ($0.13 loss per share) vs $60.7M ($0.22) YoY; non-GAAP net loss $36.8M ($0.12).
August 7, 2025, 7:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01

PacBio Q2 revenue up 10.5% YoY to $39.8M; GAAP net loss narrows to $41.9M

GAAP net loss per share of $0.14 improved from $0.64 YoY; non-GAAP EPS -$0.13 vs -$0.20.
June 6, 2025, 7:59 PM ET other materiality 0.60 neutral item 5.02 item 5.07 item 9.01

Stockholders approve 23M share increase to 2020 Equity Plan; Annual meeting results

Stockholders approved 23M share increase to 2020 Equity Plan: 85.4M for, 43.6M against, 56.4M broker non-votes.
May 8, 2025, 7:59 PM ET earnings materiality 0.75 negative item 2.02 item 9.01

PacBio Q1 GAAP net loss $426M on restructuring; consumable revenue record, non-GAAP loss narrows

Revenue $37.2M, down 4% YoY; consumable revenue record $20.1M (+26% YoY).
April 9, 2025, 7:59 PM ET earnings materiality 0.70 negative item 2.02 item 2.05 item 9.01

PacBio reports preliminary Q1 revenue $36.9M, down 5% YoY; cuts annual opex run rate by $45-50M

Preliminary Q1 2025 revenue $36.9M vs $38.8M YoY; instrument revenue fell to $10.8M from $19.0M.
March 27, 2025, 7:59 PM ET leadership materiality 0.50 positive item 5.02 item 7.01 item 9.01 ◈ executive_change ×2

PacBio appoints Jim Gibson as CFO, effective March 31, 2025

Jim Gibson appointed CFO effective March 31, 2025; Christian Henry ceases as interim CFO.
March 13, 2025, 7:59 PM ET other material materiality 0.55 neutral item 1.01 item 2.03

Pacific Biosciences extends Menlo Park lease to 2034, gets $11.6M rent abatement

Lease term extended to April 30, 2034 from Oct 31, 2027; 180,231 sq ft.
February 13, 2025, 6:59 PM ET earnings materiality 0.80 negative item 2.02 item 9.01

PacBio Q4 rev $39.2M (-33% YoY), $90M impairment, non-GAAP loss $55.3M

Revenue $39.2M vs $58.4M prior year; instrument revenue fell to $15.3M from $35.1M.
February 7, 2025, 6:59 PM ET leadership materiality 0.15 neutral item 5.02

Pacific Biosciences appoints Smith to Science & Technology Committee, Mohr as Audit chair

Christopher M. Smith appointed to Science and Technology Committee effective February 6, 2024.
January 30, 2025, 6:59 PM ET leadership materiality 0.30 neutral item 5.02 item 7.01 item 9.01 ◈ executive_change ×2

PacBio appoints NeoGenomics CEO Chris Smith to board; David Meline resigns

Chris Smith, CEO of NeoGenomics (NEO), appointed to PacBio Board effective Jan 30, 2025.
January 14, 2025, 6:59 PM ET other material materiality 0.70 negative item 2.02 item 8.01 item 9.01

PacBio reports preliminary Q4 revenue $39.2M, down 33% YoY; Vega system shipped ahead of schedule

Preliminary Q4 revenue $39.2M vs $58.4M prior year (-33%); full year $154M vs $200M (-23%).
December 13, 2024, 6:59 PM ET leadership materiality 0.50 neutral item 5.02 item 9.01

Pacific Biosciences discloses CCO Jeff Eidel's separation terms: $485K severance, 12-month COBRA

Jeff Eidel's employment as CCO ended Nov 15, 2024; separation agreement signed Dec 6, effective Dec 13.
December 13, 2024, 6:59 PM ET other material materiality 0.50 neutral item 5.02

Pacific Biosciences amends CEO/COO severance: lump sum 12-18 months salary, extended change-of-control window

CEO Christian Henry receives lump sum cash severance equal to 18 months of base salary.
December 6, 2024, 6:59 PM ET leadership materiality 0.60 neutral item 5.02

Pacific Biosciences CFO Susan G. Kim resigns; CEO Christian Henry appointed interim CFO

Susan G. Kim resigned as CFO and principal financial officer effective December 6, 2024.
November 22, 2024, 6:59 PM ET debt materiality 0.80 neutral item 1.01 item 2.03 item 3.02 item 9.01

Pacific Biosciences exchanges $459M 2028 notes for $200M new notes, shares, and $50M cash

Exchanged $459M of 1.50% 2028 notes for $200M new 1.50% notes due 2029, 20,451,570 shares, and $50M cash.
November 12, 2024, 6:59 PM ET leadership materiality 0.50 neutral item 5.02 ◈ executive_change

Pacific Biosciences CCO Jeff Eidel to depart Nov 15 amid commercial restructuring

Jeff Eidel notified of separation as Chief Commercial Officer on November 11, 2024.
November 7, 2024, 6:59 PM ET debt materiality 0.70 positive item 1.01 item 2.03 item 8.01 item 3.02 item 9.01

PacBio exchanges $459M 2028 notes for $200M 2029 notes, 20.5M shares, $50M cash

Exchanged $459M of 1.5% 2028 notes for $200M new 1.5% 2029 notes, 20.45M shares, and $50M cash.
November 7, 2024, 6:59 PM ET earnings materiality 0.75 negative item 2.02 item 5.02 item 9.01 ◈ executive_change

PacBio Q3 revenue falls 28% to $40M; CFO resigns; notes exchange with SoftBank

Revenue $40.0M (-28% YoY); instrument revenue $16.8M (down from $34.7M); 22 Revio systems shipped.
August 7, 2024, 7:59 PM ET other material materiality 0.70 negative item 2.05

Pacific Biosciences estimates $27M in charges for expense reduction plan; San Diego office closure

Total charges estimated at $27M in fiscal 2024, including $10M compensation, $12M lease costs, $4M inventory.
August 7, 2024, 7:59 PM ET earnings materiality 0.75 negative item 2.02 item 9.01

PacBio Q2 revenue down 24% to $36M; GAAP net loss $173M includes $93M goodwill impairment

Revenue of $36.0M vs $47.6M YoY; instrument revenue fell to $14.7M from $29.9M.
June 20, 2024, 7:59 PM ET other material materiality 0.60 neutral item 5.02 item 5.07 item 5.03 item 9.01

PACB shareholders approve 20M share increase, board declassification, officer exculpation

Stockholders approved amendment to 2020 Equity Incentive Plan, adding 20,000,000 shares for issuance.
May 9, 2024, 7:59 PM ET earnings materiality 0.80 negative item 2.02 item 9.01 ◈ Earnings Releases ×2

PacBio Q1 revenue flat at $38.8M; net loss $78.2M; cuts 195 jobs to reduce expenses

Revenue $38.8M (flat YoY); instrument revenue down 8% to $19.0M; consumables up 14% to $16.0M.
April 16, 2024, 7:59 PM ET earnings materiality 0.85 negative item 2.02 item 2.05 item 8.01 item 9.01 ◈ Earnings Releases ×2

PacBio reports preliminary Q1 rev $38.8M (flat YoY), slashes FY2024 guidance to $170-200M, cuts costs $50-75M

Preliminary Q1 2024 revenue $38.8M, roughly flat vs $38.9M in prior-year period.